LungTalk for Increasing Lung Cancer Screening

Overseen by Lisa Carter-Bawa, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Hackensack Meridian Health

Disqualifiers: Lung cancer, Impaired decision-making, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial uses a program called LungTalk and Facebook ads to encourage high-risk individuals to get screened for lung cancer. The goal is to increase awareness and motivate people to undergo screening. By targeting those at higher risk, the intervention aims to catch lung cancer early when it is more treatable.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment LungTalk for increasing lung cancer screening?

The research suggests that tools and interventions that enhance shared decision-making, like the Risk-Based NLST Outcomes Tool and decision aids, can improve patient understanding and decision-making about lung cancer screening. These findings imply that similar tools, such as LungTalk, may also be effective in increasing lung cancer screening by facilitating better communication and informed decision-making. ^{1 2 3 4 5}

How is the LungTalk treatment different from other lung cancer screening methods?

LungTalk is unique because it uses a digital communication tool to increase awareness and knowledge about lung cancer screening, leveraging social media to reach high-risk individuals who may not be aware of or have access to traditional screening methods. ^{1 6 7 8 9}

Research Team

Lisa Carter-Bawa, PhD

Principal Investigator

Hackensack Meridian Health

Eligibility Criteria

The INSPIRE-Lung Study is for individuals who have a history of heavy smoking (at least 20 pack-years), including current smokers or those who quit within the last 15 years. It's not for people who've already had lung cancer screening, are being monitored for lung nodules, have been diagnosed with lung cancer, or have impaired decision-making.

Inclusion Criteria

You have smoked an average of one pack a day for 20 years or more.

I am a current smoker or quit smoking within the last 15 years.

Exclusion Criteria

I am capable of making my own decisions.

I have had a low-dose CT scan for lung cancer and am being monitored for lung nodules.

I have been diagnosed with lung cancer.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive either the tailored health communication intervention 'LungTalk' or the non-tailored ACS Lung Screening Informational Video

6 months

Online intervention

Follow-up

Participants are monitored for effectiveness of the intervention, including self-efficacy, perceived risk, and screening uptake

6 months

Long-term Monitoring

Reaching screening eligible individuals via social media and measuring engagement metrics

Up to 4 years

Treatment Details

Interventions

• LungTalk (Behavioral Intervention)
• Non-tailored intervention - Standard of practice (Behavioral Intervention)

Trial Overview This study tests 'LungTalk', a communication intervention aimed at increasing lung cancer screening rates among high-risk groups using Facebook-targeted advertisements. It compares LungTalk to standard practices without tailored interventions.

Participant Groups

Group I: Tailored health communication intervention (LungTalk) Experimental Treatment 1 Intervention

Participants will receive the tailored health intervention "LungTalk". LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening Participation.

Group II: Non-tailored Intervention Active Control 1 Intervention

Participants will receive non-tailored American Cancer Society (ACS) Lung Screening Informational Video as per standard of care. ACS Lung Screening Informational Video (ACS LSIV) is a non-tailored 5-minute video from the American Cancer Society about lung cancer screening designed for the lay individual.

Who Is Running the Clinical Trial?

Hackensack Meridian Health

Lead Sponsor

Trials

141

Recruited

42,900+

Dr. Gregory J. Rokosz

Hackensack Meridian Health

Chief Medical Officer since 2023

DO from New York College of Osteopathic Medicine, JD from Seton Hall University School of Law

Robert C. Garrett

Hackensack Meridian Health

Chief Executive Officer since 2016

Bachelor's degree in Health Administration from Washington University in St. Louis

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School

Findings from Research

The study aims to implement a tailored approach to shared decision-making (SDM) for lung cancer screening (LCS) within the VA New England Health Care Network, addressing barriers at multiple levels to enhance patient-centered care.

By evaluating the effectiveness of this multilevel implementation strategy, the research seeks to improve the quality of SDM for LCS, potentially informing nationwide practices and promoting better patient-provider interactions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Implementing Shared Decision-Making for Lung Cancer Screening across a Veterans Health Administration Hospital Network: A Hybrid Effectiveness-Implementation Study Protocol. Khanna, A., Fix, GM., McCullough, MB., et al.[2022]

A single-page, paper-based encounter decision aid (EDA) used during shared decision-making visits for lung cancer screening significantly reduced patient decisional conflict, as indicated by a drop in the Decisional Conflict Scale score from 35.0 to 0.2 (p < 0.001).

While 28% of patients understood the mortality benefit of lung cancer screening after the visit, a much higher percentage (82%) grasped the frequency of abnormal screening results, highlighting the need for improved patient education on the mortality benefits of screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pilot Study of an Encounter Decision Aid for Lung Cancer Screening. Ito Fukunaga, M., Balwan, A., Janis, JA., et al.[2023]

A systematic review of 24 studies involving 6689 patients found that only 57% adhered to Lung-RADS-recommended screening intervals, indicating suboptimal compliance that could reduce the effectiveness of lung cancer screening.

Adherence rates were significantly higher for patients with Lung-RADS scores of 3 to 4 compared to those with scores of 1 to 2, suggesting that patients with more concerning findings are more likely to follow up with screenings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis. Lin, Y., Fu, M., Ding, R., et al.[2022]

A randomized trial involving 298 Maryland Tobacco Quitline callers showed that providing lung cancer screening (LCS) education through print materials led to higher engagement (75% read the materials) compared to web-based materials (61.6%).

Despite similar rates of scheduling or completing LCS between the two groups (around 43%), the study highlights that offering educational materials in preferred formats (print or web) can enhance awareness and potentially increase screening rates among eligible individuals.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The tobacco quitline setting as a teachable moment: The Educating Quitline Users About Lung (EQUAL) cancer screening randomized trial. Webster, M., Whealan, J., Williams, RM., et al.[2023]

A focus group study involving 54 participants from Appalachian Kentucky revealed that most individuals were previously unaware of lung cancer screening with low-dose computed tomography (LDCT), highlighting the need for effective awareness campaigns.

Participants emphasized the importance of messaging that includes personal testimonies, hope, and the benefits of early detection, suggesting that communication from trusted healthcare providers is crucial for promoting lung cancer screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Identifying Community Perspectives for a Lung Cancer Screening Awareness Campaign in Appalachia Kentucky: The Terminate Lung Cancer (TLC) Study. Cardarelli, R., Roper, KL., Cardarelli, K., et al.[2018]

References

1. England pubmed.ncbi.nlm.nih.gov

Patient Perspectives on the Risk-Based NLST Outcomes Tool for Lung Cancer Screening. [2022]

2. England pubmed.ncbi.nlm.nih.gov

Effectiveness of a Patient Education Class to Enhance Knowledge about Lung Cancer Screening: a Quality Improvement Evaluation. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Implementing Shared Decision-Making for Lung Cancer Screening across a Veterans Health Administration Hospital Network: A Hybrid Effectiveness-Implementation Study Protocol. [2022]

4. England pubmed.ncbi.nlm.nih.gov

Pilot Study of an Encounter Decision Aid for Lung Cancer Screening. [2023]

5. United States pubmed.ncbi.nlm.nih.gov

Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis. [2022]

6. United States pubmed.ncbi.nlm.nih.gov

Leveraging social media to increase lung cancer screening awareness, knowledge and uptake among high-risk populations (The INSPIRE-Lung Study): Study protocol of design and methods of a community-based randomized controlled trial. [2023]

7. England pubmed.ncbi.nlm.nih.gov

Adapting Community Educational Programs During the COVID-19 Pandemic: Comparing the Feasibility and Efficacy of a Lung Cancer Screening Educational Intervention by Mode of Delivery. [2023]

8. England pubmed.ncbi.nlm.nih.gov

The tobacco quitline setting as a teachable moment: The Educating Quitline Users About Lung (EQUAL) cancer screening randomized trial. [2023]

9. England pubmed.ncbi.nlm.nih.gov

Identifying Community Perspectives for a Lung Cancer Screening Awareness Campaign in Appalachia Kentucky: The Terminate Lung Cancer (TLC) Study. [2018]